Sartorius spends $750M for Danaher's life science platform biz

Merger
The deal between Sartorius and Danaher should be done by the first quarter next year. (daizuoxin/iStock/Getty Images Plus/Getty Images)

German biopharma services company Sartorius is to spend three-quarters of a billion dollars to buy up Danaher’s life science portfolio.

This comes as part of a deal in which Danaher, another biopharma services company, is itself in the middle of: buying the biopharma business of GE Life Sciences for around $20 billion. This sell-off to Sartorius has been promoted by the GE deal, likely appeasing regulators.  

The deal is set to include the label-free biomolecular characterization (known as FortéBio), chromatography hardware and resins, and microcarriers (known as SoloHill) businesses.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The deal, which hinges upon the GE buyout completing, should be done by the first quarter next year.

“The portfolio proposed for acquisition represents an excellent strategic fit with Sartorius,” said Dr. Joachim Kreuzburg, Sartorius’ CEO.

“With the Octet platform of FortéBio, we will add a broadly accepted and differentiated technology for advancing and simplifying drug discovery to our lab division’s portfolio. The chromatography hardware and resins and the microcarrier businesses broaden our strong bioprocessing offering, particularly in the downstream area. We look very much forward to welcoming the new teams to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers.”

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.